Trinity Biotech plc announced the appointment of Avinash Kale as Continuous Glucose Monitor (CGM) Programme Director. His appointment is a critical step forward in advancing the Company?s recently acquired CGM technology and in driving its innovation and development to bring an advanced CGM solution to the global market. Mr. Kale, a seasoned MedTech R&D, PMO & Innovation leader, with extensive global industry experience recently joined Trinity Biotech?s team in Ireland, from Philips Healthcare, The Netherlands.

His career spans roles of increasing responsibility across Fortune 500+ firms Philips Healthcare Netherlands, Dell China, TATA India and Europe based scale-ups and start-ups. Mr. Kale has held key leadership positions, as Global Director of Engineering, Chief Technology Officer (CTO), Global Medical Device PMO, Head of Embedded Systems, R&D Program Management (PM), and Systems Engineering by steering global partners eco-system and teams across multiple sites and delivering cutting-edge solutions that drive meaningful innovations. Throughout his career, he has been a catalyst for impactful initiatives, including global product design & development, LEAN R&D, program leadership, business integration, emerging market initiatives, R&D Process innovation, product innovation, enabling technologies implementation, and transformation & change management, demonstrating his expertise in the end-to-end medical device solution life cycle.

Mr. Kale holds a degree in Electronics and Telecommunications from Pune University, India, and has successfully completed the Leading Digital Transformation in Healthcare Executive Programme from Harvard Medical School.